The CDC received FDA approval for a highly sensitive influenza PCR assay
In 2008, the U.S. Centers for Disease Control and Prevention (CDC) received U.S. Food and Drug Administration (FDA)…
CDC | Diagnostics | Influenza | Therapeutics
The Influenza Reagent Resource was established by the CDC
In 2008, the Influenza Reagent Resource (IRR) was established by the Centers for Disease Control and Prevention (CDC)…
Merck voluntarily recalled 12 million doses of Haemophilus influenzae type b
On Dec. 12, 2007, Merck voluntarily recalled 1.2 million doses of Haemophilus influenzae type b (Hib) vaccines due…
ACIP voted to recommend the use of FluMist
On Oct. 26, 2007, the Immunization Practices Advisory Committee (ACIP) voted to recommend the use of FluMist, the…
FDA approved Afluria, a new inactivated influenza vaccine for use in people age 18 years and older
On Sept. 28, 2007, the U.S. Food and Drug Administration (FDA) approved an Australian-made influenza vaccine called Afluria…
FDA approved use of FluMist nasal-spray influenza vaccine in children age 2-5 years
On Sept. 20, 2007, the U.S. Food and Drug Administration (FDA) approved use of FluMist nasal-spray influenza vaccine…
Nonpharmaceutical interventions implemented by U.S. cities during the 1918-1919 influenza pandemic
On Aug. 8, 2007, JAMA reported that research demonstrated a strong association between early, sustained, and layered application…
Biotechnology | CDC | Diagnostics | Infectious Disease | Influenza | NIH | Polio | Vaccine | WHO
U.S. CDC announced International Health Regulations had gone into effect for the U.S.
On Jul. 20, 2007, the U.S. Centers for Disease Control and Prevention (CDC) announced in MMWR that revised…
HHS announced $175 million to assist states in pandemic influenza preparedness efforts
On Jul. 17, 2007, The U.S. Department of Health and Human Services (HHS) announced it was providing states,…
HHS awarded $132.5 million to Sanofi Pasteur and MedImmune over five years to retrofit existing domestic vaccine manufacturing facilities
On Jun. 14, 2007, the U.D. of Health and Human Services (HHS) awarded $132.5 million to Sanofi Pasteur…
Biotechnology | COVID-19 | Diagnostics | Disease | Influenza | Plague | Therapeutics | Vaccine
Fort Knox prepared for pandemic outbreak scenarios
On Jun. 7, 2007, years before the COVID-19 pandemic swept across the globe, a group of about 100…
FDA approved the H5N1 vaccine, the first vaccine approved for avian flu
On Apr. 17, 2007, Sanofi announced that the U.S. Food and Drug Administration (FDA) had licensed its H5N1…
CDC published Interim Pre-pandemic Planning Guidance Strategy for Pandemic Influenza Mitigation in the U.S.
On Feb. 1, 2007, the Centers for Disease Control and Prevention (CDC) released its long-awaited disease containment strategy…
FDA licensed the refrigerator formulation of FluMist
On Jan. 9, 2007, the U.S. Food and Drug Administration (FDA) announced it had approved a refrigerated form…
Biotechnology | CDC | Influenza | Therapeutics | Vaccine
Human infection with a novel influenza virus was added to the nationally notifiable disease list
On Jan. 9, 2007, the Executive Committee of the Council of State and Territorial Epidemiologists approved an interim…
Sanofi Pasteur delivered H5N1 vaccine for U.S. government pandemic initiatives
On Feb. 6, 2006, Sanofi pasteur announced it had delivered more H5N1 vaccine to the U.S. government including…
Biotechnology | CDC | Diagnostics | Influenza | Vaccine
CDC stopped recommending adamantanes during 2005 season after high levels of influenza A (H3N2) virus resistance
On Jan. 17, 2006, the Centers for Disease Control and Prevention (CDC) announced that it had stopped recommending…
Federal Medicare rule required all long-term care facilities to offer vaccination for influenza and pneumococcal disease
On Oct. 7, 2005, a new Federal Medicare rule became effective that required all long-term care facilities to…
The genome of the 1918 H1N1 pandemic influenza virus was sequenced
On Oct. 7, 2005, Jeffery Taubenberger, AH Reid, AE Krafft, Karen Bijwaard and Thomas Fanning published a report…
An inactivated, injectable influenza vaccine was licensed
On Aug. 31, 2005, the inactivated, injectable influenza vaccine (Fluarix) by GlaxoSmithKline (GSK) was licensed. The vaccine was…
HHS awarded a contract for $97 million to Sanofi Pasteur to develop cell culture-based influenza vaccines for the U.S.
On Apr. 1, 2005, Sanofi pasteur was awarded a five-year $97 million contract from the U.S. Department of…
HHS Pandemic Influenza Plan was published
In 2005 and 2006, the White House Homeland Security Council outlined the National Strategy for Pandemic Influenza to…
A significant shortage of influenza vaccine occurred in the U.S.
On Aug. 25, 2004, a significant shortage of influenza vaccine occurred in the U.S. as a result of…
Contracts awarded to Aventis Pasteur and Chiron to develop vaccine against H5N1 avian influenza virus
On May 27, 2004, the National Institute of Allergy and Infectious Diseases (NIAID) announced it had awarded contracts…
ACIP voted to recommend influenza vaccination for children aged 6 to 23 months
On Oct. 15, 2003, the Immunization Practices Advisory Committee (ACIP) voted to recommend that children 6 to 23…
The first nasally administered influenza vaccine (FluMist by MedImmune) was licensed
On Jun. 17, 2003, the first nasally administered influenza vaccine (FluMist by MedImmune) was licensed. This live influenza…
The ACIP encouraged that children 6 to 23 months of age be vaccinated annually against influenza
On Jan. 1, 2003, the Advisory Committee on Immunization Practices (ACIP) encouraged that children 6 to 23 months…
Public health officials were concerned about re-emergence of H5N1 avian influenza
In 2003, public health officials reported the re-emergence of H5N1 avian influenza for the first time since an…
Roche received FDA approval of TAMIFLU, first pill to treat most common strains of influenza (A&B)
On Oct. 27, 1999, Hoffmann-La Roche and Gilead Sciences announced that Roche’s TAMIFLU (oseltamivir phosphate) had been approved…
Neuraminidase inhibitors Tamiflu and Relenza were licensed to treat influenza infection
On Oct. 27, 1999, Hoffmann-La Roche and Gilead Sciences announced that Roche’s TAMIFLU™ (oseltamivir phosphate) has been approved…